Ładuje się......
Phase I Trial of Fludarabine, Bortezomib and Rituximab for Relapsed and Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma
Based on the hypothesis that bortezomib may potentiate fludarabine activity by inhibiting DNA repair, we designed a phase I trial using this combination with rituximab in patients with relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Twenty-four patients were enrolled. Non-Hodg...
Zapisane w:
| Główni autorzy: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2009
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2827854/ https://ncbi.nlm.nih.gov/pubmed/19656151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07836.x |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|